Company intelligence / Profile preview
Alnylam Pharmaceuticals
Cambridge, Massachusetts, United Statesalnylam.com ↗
- Ownership
- Public · ALNY
- Employees
- ~2100
- Development stage
- Other
01
Overview
Alnylam is the global leader in RNA interference therapeutics with five approved medicines as of 2025. Its drugs have demonstrated significant efficacy for rare genetic diseases such as hATTR amyloidosis, acute hepatic porphyria, primary hyperoxaluria type 1, and cardiovascular disease. The company continues to expand its clinical pipeline into new indications and organ systems beyond the liver
- Therapeutic areas
- Rare DiseasesCardiovascular
- Modalities
- RNA interference (RNAi)Small interfering RNA (siRNA)
- Industry
- Biotech
02
Drug pipeline
56 assets55 more assets in the full pipeline.
03
Partnerships
Novartis (Leqvio)Regulus Therapeutics (co-founded with Ionis)past partnerships with Medtronic, Biogen Idec/Biogen Inc., Hoffmann-La Roche/Ionis Pharmaceuticals
04
Financials
- Market cap
- $21B
- Total revenue
- $3.7B
- Enterprise value
- $18.7B
Beyond the preview
Go deeper on Alnylam Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Alnylam Pharmaceuticals.